Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain



    MONTREAL, March 18 /CNW Telbec/ - Aegera Therapeutics announced today the
initiation of a Phase 1, first-in-man, clinical trial for AEG33773, a novel,
orally bioavailable small molecule in development for the treatment of painful
diabetic neuropathy. The Phase I study will evaluate the safety, tolerability
and pharmacokinetic profile of AEG33773 using a randomized, double blind,
placebo controlled, single ascending dose design in healthy male volunteers.
    Aegera completed a comprehensive pre-clinical development program on
AEG33773, culminating in regulatory clearance from Health Canada and treatment
of a first patient, in less than 12 months.
    "We are extremely excited about the potential for AEG33773 to treat
painful diabetic neuropathy and to expand to other pain and neuropathy
indications, based on our extensive preclinical experience with this family of
compounds in multiple models of pain and neuropathy," commented Dr. Jon
Durkin, Vice-President Research and Preclinical Development at Aegera.
    "This important milestone was achieved in record time, as the Aegera team
has successfully filed regulatory applications for two potential blockbuster
compounds, AEG33773 and AEG40826, in the last three months while initiating
multiple Phase 2 trials for our lead program AEG35156. Aegera now has four
unique programs in clinical development and is poised to deliver significant
clinical data over the next 12-18 months" added Dr. Michael J. Berendt,
Aegera's President and CEO.

    About AEG33773

    AEG33773 was developed as an orally bioavailable small molecule compound
which provides acute pain relief in preclinical models of neuropathic and
inflammatory pain. In addition, AEG33773's unique mechanism of action has
demonstrated excellent in vivo activity in models of diabetic neuropathy with
respect to its ability to not only prevent, but also to reverse established
neuropathies.

    About Aegera Therapeutics Inc.

    Aegera Therapeutics is a clinical stage biotechnology company focused on
developing drugs that control apoptosis to address major unmet medical needs.
In addition to AEG33773, Aegera has three programs in clinical development for
oncology indications:

    
    - AEG35156 targets the key anti-apoptotic protein XIAP, and is currently
      in multiple Phase II human clinical trials for the treatment of solid
      tumors and leukemia;
    - AEG41174 is a novel, non-ATP competitive, small molecule tyrosine
      kinase inhibitor targeting therapeutically significant kinases
      including JAK2 and Bcr-Abl, and is currently in Phase 1 clinical
      studies;
    - AEG40826 (HGS1029) is a small molecule IAP inhibitor that has shown
      promising preclinical activity alone and in combination with other
      anti-neoplastic agents across a broad range of cancers.  A license and
      collaboration agreement was executed in December 2007 whereby Human
      Genome Sciences, Inc. (Nasdaq:   HGSI) acquired exclusive rights to
      develop and commercialize small-molecule IAP inhibitors in oncology.
    

    Website: www.aegera.com




For further information:

For further information: Donald Olds, MSc, MBA, Chief Operating Officer
& CFO, Aegera Therapeutics Inc., (514) 288-5532 * 295, donald.olds@aegera.com

Organization Profile

AEGERA THERAPEUTICS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890